Source:http://linkedlifedata.com/resource/pubmed/id/17233770
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2007-2-22
|
| pubmed:abstractText |
We evaluated the additional benefit of Technetium(99)-sestamibi (99mTc-MIBI) scanning in comparison with standard X-ray techniques for multiple myeloma patients either at diagnosis or during follow-up. Between February 2001 and January 2005, 397 whole body scans were acquired. On 229 scans performed at diagnosis, 146 (64%) were positive and 81 cases have discordant X-ray results. The sensitivity of 99mTc-MIBI and X-ray were 77% and 45% respectively. As a result of 99mTc-MIBI, 40% of asymptomatic myeloma patients were up-staged. The positivity of 99mTc-MIBI correlated significantly with all of the most relevant clinical and biological parameters. Multivariate analysis selected only high reactive C protein (P = 0.0005), bone marrow infiltration (P = 0.02) and bone pain (P = 0.002) as factors affecting 99mTc-MIBI pattern. In 22 patients with solitary myeloma, 99mTc-MIBI was positive in 86% of cases and detected more disease sites than X-ray. Among 168 scans performed during follow-up, 99mTc-MIBI presented high specificity in patients showing a complete response (CR; 86%), and correlated with myeloma activity and with response to therapy. At multivariate analysis, a positive pattern correlated with bone marrow infiltration (P = 0.002) and disease status other than CR (P = 0.03). We conclude that 99mTc-MIBI scanning is an additional diagnostic tool with a high specificity for the staging and the follow-up of multiple myeloma patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0007-1048
|
| pubmed:author |
pubmed-author:AgostiniVanessaV,
pubmed-author:AscoliGiorgioG,
pubmed-author:BerbelliniAlfonsoA,
pubmed-author:BrianzoniErnestoE,
pubmed-author:BrunoriMarinoM,
pubmed-author:CambioliFilippoF,
pubmed-author:CatariniMassimoM,
pubmed-author:CorvattaLauraL,
pubmed-author:GradariMarinellaM,
pubmed-author:IsidoriAlessandroA,
pubmed-author:LeoniPietroP,
pubmed-author:MarconiMonicaM,
pubmed-author:MeleAnnaA,
pubmed-author:NonniMarcoM,
pubmed-author:OffidaniMassimoM,
pubmed-author:SpinelliAurelianoA,
pubmed-author:VisaniGiuseppeG
|
| pubmed:issnType |
Print
|
| pubmed:volume |
136
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
729-35
|
| pubmed:meshHeading |
pubmed-meshheading:17233770-Adult,
pubmed-meshheading:17233770-Aged,
pubmed-meshheading:17233770-Aged, 80 and over,
pubmed-meshheading:17233770-Antineoplastic Agents,
pubmed-meshheading:17233770-Bone Marrow,
pubmed-meshheading:17233770-C-Reactive Protein,
pubmed-meshheading:17233770-Female,
pubmed-meshheading:17233770-Follow-Up Studies,
pubmed-meshheading:17233770-Humans,
pubmed-meshheading:17233770-Male,
pubmed-meshheading:17233770-Middle Aged,
pubmed-meshheading:17233770-Multiple Myeloma,
pubmed-meshheading:17233770-Neoplasm Invasiveness,
pubmed-meshheading:17233770-Neoplasm Staging,
pubmed-meshheading:17233770-Radiopharmaceuticals,
pubmed-meshheading:17233770-Sensitivity and Specificity,
pubmed-meshheading:17233770-Technetium Tc 99m Sestamibi,
pubmed-meshheading:17233770-Treatment Outcome
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans.
|
| pubmed:affiliation |
Department of Haematology, San Salvatore Hospital, Pesaro, Italy.
|
| pubmed:publicationType |
Journal Article,
Multicenter Study,
Evaluation Studies
|